Zacks Investment Research·2d ago
IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpIronwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
Ironwood Pharmaceuticals has demonstrated exceptional operating leverage, with operating margins expanding from 14.7% in 2024Q1 to 70.2% in 2026Q2, driven by a 69% reduction in SG&A and stable R&D.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.36+11.4% vs $0.32 | $133M+10.9% vs $120M |
Q3 2026 Aug 6, 2026 | $0.31-3.1% vs $0.32 | $113M-1.6% vs $115M |
Q2 2026 May 7, 2026 | $0.24+242.9% vs $0.07 | $107M+15.6% vs $92M |
Q1 2026 Feb 25, 2026 | -$0.01-150.0% vs $0.02 | $48M-6.3% vs $51M |
Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.
Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt - CEO & Director Tammi Gaskins - Senior Vice President & Chief Commercial Officer Jeffrey Silber - Chief Medical Officer, Head of Research & Drug Development Ronald Silver - Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Jeff Ruberti - Chief Strategy Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Nicholas Mattiacci Tom Rosenfeld Presentation Operator Hello, everyone. My name is Megan, and I will be your conference operator today.
Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the gastrointestinal drug's performance.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.
Benchmark IRWD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ironwood Pharmaceuticals, Inc. (IRWD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.39 | $722.65M | 4.87 | -15.72% | 37.38% | — | — | |
| $132.04 | $8.49B | 27.67 | -89.41% | 62.04% | 42.83% | — | |
| $2.88 | $711.44M | -12.98 | 22.09% | -11.85% | -35.3% | — | |
| $5.22 | $78.21M | -7.37 | 17.57% | -33.92% | -47.8% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% |
Ironwood Pharmaceuticals, Inc. (IRWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ironwood Pharmaceuticals, Inc. (IRWD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 18, 2026·SEC
Jun 15, 2026·SEC
Get notified when IRWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ironwood Pharmaceuticals, Inc. (IRWD) stock FAQ — growth, dividends, profitability & financials explained
Ironwood Pharmaceuticals, Inc. (IRWD) reported $400.3M in revenue over the trailing twelve months. Revenue was $296.2M in fiscal year 2025. That is 2730% more than the $10.5M of fiscal year 2007.
Ironwood Pharmaceuticals, Inc. (IRWD) grew revenue by 18.1% over the trailing twelve months, compared with the twelve months before.
Yes. Ironwood Pharmaceuticals, Inc. (IRWD) earned $149.6M in net income over the trailing twelve months (a 37.4% net margin).
Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in free cash flow in fiscal year 2025.
